Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone in a preclinical model of Parkinson’s disease

STOCKHOLM, SWEDEN – July 5, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented results from a study on a preclinical model of Parkinson’s disease as a poster at the 6th World Parkinson Congress in Barcelona, July 4-7. The poster shows how the company’s clinical drug candidate golexanolone reverses fatigue, anxiety, depression, and some cognitive and motor alternations in the disease model.

The results are generated from a preclinical study conducted in collaboration with Dr. Vicente Felipo at the Laboratory of Neurobiology, Centro de Investigación Principe Felipe in Valencia, Spain. The preclinical model of Parkinson’s disease is used to evaluate the effect of golexanolone on several hallmark symptoms observed in patients with Parkinson’s disease, such as fatigue, anxiety, depression, cognitive impairment, and alterations in motor function. Top-line results from the study were first announced by Umecrine Cognition in January 2023.

“Umecrine Cognition’s drug candidate golexanolone has the potential to improve the quality of life for patients with Parkinson’s disease, and it’s a great opportunity for our portfolio company to present its encouraging preclinical data on symptom relief at this accredited event,” says Viktor Drvota, CEO of Karolinska Development.

Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's most advanced drug candidate, golexanolone, is currently being evaluated in primary biliary cholangitis (PBC) and hepatic encephalopathy (HE).

Karolinska Development's ownership in Umecrine Cognition amounts to 73 percent.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development ABPhone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development ABKarolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient’s lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com.

Attachment